# A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

> **NCT05763004** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **ImmunOs Therapeutics AG** · enrollment: 140 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** IOS-1002
- **DRUG:** IOS-1002 + KEYTRUDA® (pembrolizumab)

## Key facts

- **NCT ID:** NCT05763004
- **Lead sponsor:** ImmunOs Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05763004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05763004, "A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05763004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*